Schwab Charles Investment Management Inc. raised its holdings in AveXis Inc (NASDAQ:AVXS) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,902 shares of the company’s stock after acquiring an additional 1,389 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in AveXis were worth $12,163,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of AVXS. Westfield Capital Management Co. LP acquired a new stake in AveXis in the 3rd quarter valued at about $39,563,000. Perceptive Advisors LLC lifted its holdings in AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock valued at $64,923,000 after acquiring an additional 400,000 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after acquiring an additional 352,456 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in AveXis by 174.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 205,640 shares of the company’s stock valued at $19,892,000 after acquiring an additional 130,640 shares during the last quarter. Finally, Eagle Asset Management Inc. lifted its holdings in AveXis by 41.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 158,528 shares of the company’s stock valued at $15,180,000 after acquiring an additional 46,835 shares during the last quarter. 82.66% of the stock is owned by institutional investors.
AVXS has been the subject of a number of research analyst reports. Chardan Capital reissued a “buy” rating on shares of AveXis in a report on Thursday, November 2nd. Royal Bank of Canada reaffirmed a “hold” rating and set a $92.00 price objective on shares of AveXis in a research note on Thursday, November 2nd. Bank of America reduced their price objective on shares of AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a research note on Friday, November 10th. ValuEngine lowered shares of AveXis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub lowered shares of AveXis from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and sixteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $122.30.
AveXis Inc (AVXS) opened at $123.73 on Thursday. AveXis Inc has a twelve month low of $61.43 and a twelve month high of $128.00.
AveXis (NASDAQ:AVXS) last issued its earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91). sell-side analysts forecast that AveXis Inc will post -5.76 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “AveXis Inc (AVXS) Shares Bought by Schwab Charles Investment Management Inc.” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3231210/avexis-inc-avxs-shares-bought-by-schwab-charles-investment-management-inc.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis Inc (NASDAQ:AVXS).
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.